Advances of the influence of nonalcoholic fatty liver disease on the pharmacokinetics

Abstract

Abstract: Nonalcoholic fatty liver disease(NAFLD) is one most common chronic liver disease,and it is a big threat against people's health.Chronic liver disease is the most important causes of effects on drug disposition,and it may lead to changes of gene,mRNA and protein expression.The results of NAFLD animal models and NAFLD patients show that drug metabolic enzymes and transporters significantly change in NAFLD. Drug metabolic enzymes and transporters play important roles in drug disposition,and lead to consequences for interindividual differences in disposition kinetics, interaction profiles of clinical drugs, susceptibility to side effects and treatment efficacy.With the prevalence of NAFLD, NAFLD patients have to take more and more drugs.So this review focuses on the influence of nonalcoholic fatty liver disease on the pharmacokinetics.

Key words: Nonalcoholic fatty liver disease, Drug metabolic enzyme, Drug transporter, Pharmacokinetics, Advance

CLC Number:

R969.1

LI Rong-hui, HUANG Mei-ling, TAN Hong-yi, PEI Qi, XIANG Yu-xia, YANG Guo-ping. Advances of the influence of nonalcoholic fatty liver disease on the pharmacokinetics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1065-1075.

References

[1] Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease[J]. Drug Metab Reviews,2011,43(3):317-734.
[2] Browning JD, Szczepaniak LS, Dobbins R, et al.Prevalence of hepatic steatosis in an urban population in the United States impact of ethnicity[J].Hepatology, 2004,40(6):1387-1395.
[3] 朱方超, 黄智铭.非酒精性脂肪肝危险因素流行病学论述[J].实用医学杂志, 2010,26(18):3452-3454.
[4] Nicole J,Barshop MD, Edmund V,et al. Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease[J]. J Pediatr Gastroenterol Nutr,2011,52(2):198-202.
[5] Peng Li,Thomas A,Robertson, et al. Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis[J]. Drug Metab Dispos,2011,39(4):571-579.
[6] 黄原原,张浩,阳国平,等.慢性肾功能不全对药动学影响研究进展[J].中国临床药理学与治疗学,2012,17(6):715-720.
[7] Larter CZ, Yeh MM.Animal models of NASH: getting both pathology and metabolic context right[J]. J Gastroenterol Hepatol,2008,23(11):1635-1648.
[8] Zhang WV, Ramzan I,Murray M. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis[J]. J Pharmacol Exp Ther,2007,322(2):770-777.
[9] Deng QG, She H, Cheng JH,et al.Steatohepatitis induced by intragastric overfeeding in mice[J].Hepatology,2005, 42(4):905-914.
[10] Andrew Williams J, Ruth Hyland, Barry C,et al.Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios[J]. Drug metab dispos,2004,32(11):1201-1208.
[11] Zhou SF,Yang LP,Wei MQ,et al.Insights into the structure, function, and regulation of human cytochrome P4501A2[J]. Curr Drug Metabolism,2009,10(7):713-729.
[12] Hanagama M, Inoue H, Kamiya M,et al.Gene expression on liver toxicity induced by administration of haloperidol in rats with severe fatty liver[J]. Legal Medicine,2008,10(4):177-184.
[13] Yoshinari K, Takagi S, Sugatani J, et al.Changes in the expression of cytochromes P450 and nuclear receptors in the liver of genetically diabetic db/db mice[J]. Biol Pharm Bull,2006,29(8):1634-1638.
[14] Suh YH, Kim Y, Bang JH,et al.Analysis of gene expression profiles in insulin-sensitive tissues from pre-diabetic and diabetic Zucker diabetic fatty rats[J].J Mol Endocrinol,2005,34(4):299-315.
[15] Greco D, Kotronen A, Westerbacka J, et al.Gene expression in human NAFLD[J].Am J Physiol Gastrointest Liver Physiol,2008,294(5):G1281-G1287.
[16] Donato MT, Lahoz A, Jiménez N, et al.Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts[J]. Drug metab dispos,2006,34(9):1556-1562.
[17] Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation[J]. Gastroenterology,1996, 111(6):1645-1653.
[18] Fisher CD, Lickteig AJ, Augustine LM, et al.Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease[J]. Drug Metab Dispos,2009,37(10):2087-2094.
[19] Cheng Q, Aleksunes LM, Manautou JE, et al.Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity[J]. Mol Pharmaceutics,2008,5(1):77-91.
[20] Stepanova M, Hossain N, Afendy A, et al.Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease[J]. Obes Surg,2010,20(5):640-650.
[21] Hewitt NJ, Lechón MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins,and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies[J]. Drug Metab Rev,2007,39(1):159-234.
[22] Enriquez A, Leclercq I, Farrell GC,et al.Altere expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats[J].Biochem Biophys Res Commun,1999,255(2):300-306.
[23] Osabe M, Sugatani J, Fukuyama T,et al.Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferatoractivated receptor alpha in male rats fed a high-fat and highsucrose diet[J]. Drug Metab Dispos,2008,36(2):294-302.
[24] Khemawoot P, Yokogawa K, Shimada T,et al.Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats[J]. Biochem Pharmacol,2007,73(1):155-162.
[25] Lieber CS, Leo MA, Mak KM,et al.Model of nonalcoholic steatohepatitis[J]. Am J Clin Nutr,2004,79(3):502-509.
[26] Emery MG, Fisher JM, Chien JY,et al.CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease[J]. Hepatology,2003,38(2):428-435.
[27] Chalasani N, Gorski JC, Asghar MS,et al.Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis[J].Hepatology,2003, 37(3):544-550.
[28] Orellana M, Rodrigo R, Varela N, et al. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients[J]. Hepatol Res,2006,34(1):57-63.
[29] Nakamuta M, Kohjima M, Morizono S, et al. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease[J]. Int J Mol Med,2005,16(4):631-635.
[30] Watson AM, Poloyac SM, Howard G,et al.Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse[J]. Drug Metab Dispos, 1999,27(6):695-700.
[31] Weltman MD, Farrell GC, Hall P,et al.Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis[J]. Hepatology,1998,27(1):128-133.
[32] Donato MT, Jiménez N, Serralta A, et al. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes[J]. Toxicol In Vitro, 2007,21(2):271-276.
[33] Bell LN, Temm CJ, Saxena R, et al.Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content[J]. Ann Surg,2010,251(6):1041-1048.
[34] Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2010,154(2):103-116.
[35] Koide CL, Collier AC, Berry MJ,et al. The effect of bamboo extract on hepatic biotransforming enzymes-findings from an obese-diabetic mouse model[J]. J Ethnopharmacol,2010,133(1):37-45.
[36] Chaudhary IP, Tuntaterdtum S, McNamara PJ, et al. Effect of genetic obesity and phenobarbital treatment on the hepatic conjugation pathways[J]. J Pharmacol Exp Ther,1993, 265(3):1333-1338.
[37] Younossi ZM, Baranova A, Ziegler K,et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease[J]. Hepatology,2005,42(3):665-674.
[38] Kim MS, Wang S, Shen Z,et al. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and Sprague-Dawley rats: implications of decreased glucuronidation in obese Zucker rats[J]. Drug Metab Dispos,2004,32(9):909-914.
[39] Kirpich IA, Gobejishvili LN, Bon Homme M, et al. Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease[J]. J Nutr Biochem,2011,22(1):38-45.
[40] Ho RH, Kim RB.Transporters and drug therapy: implications for drug disposition and disease[J]. Clin Pharmacol Ther,2005,78(3):260-277.
[41] 张伟,贺毅憬,周宏灏.有机阴离子转运多肽1B1 的遗传药理学进展[J].中国临床药理学与治疗学,2008,13(7):721-729.
[42] 温爱萍,徐小薇.有机阴离子转运多肽1B1的研究进展[J].中国药学杂志, 2008,43(23):1765-1769.
[43] Geier A, Dietrich CG, Grote T,et al.Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat[J]. J Hepatol,2005,43(6):1021-1030.
[44] Fisher CD, Lickteig AJ, Augustine LM, et al. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats[J].Eur J Pharmacol,2009,613(1/2/3):119-127.
[45] More VR, Slitt AL.Alteration of hepatic but not renal transporter expression in diet-induced obese mice[J]. Drug Metab Dispos,2011,39(6):992-999.
[46] Lake AD, Novak P, Fisher CD, et al.Analysis of Global and Absorption, Distribution, Metabolism, and Elimination Gene Expression in the Progressive Stages of Human Nonalcoholic Fatty Liver Disease[J]. Drug Metab Dispos,2011,39(10): 1954-1960.
[47] Lickteig AJ, Fisher CD, Augustine LM,et al.Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease[J]. Drug Metab Dispos, 2007,35(10):1970-1978.
[48] Hardwick RN, Fisher CD, Street SM, et al. Molecular Mechanism of Altered Ezetimibe Disposition in Nonalcoholic Steatohepatitis[J]. Drug Metab Dispos,2012,40(3):450-460.
[49] Vander Borght S, Libbrecht L, Katoonizadeh A, et al.Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences[J]. J Histochem Cytochem,2006,54(9):1051-1059.
[50] Prompila N, Wittayalertpanya S, Komolmit P. Hepatic cytochrome p450 2e1 activity in nonalcoholic fatty liver disease[J]. J Med Assoc Thai ,2008, 91 (5): 733-738.
[51] Schrieber SJ, Hawke RL, Wen Z, et al.Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C[J]. Drug Metab Dispos,2011,39(12):2182-2190.
[52] Schrieber SJ, Wen Z, Vourvahis M, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity[J]. Drug Metab Dispos,2008,36(9): 1909-1916.